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Abstract
The limited availability of deceased human organs and cells for the purposes of clinical 
transplantation remains critical worldwide. Despite the increasing utilization of ‘high-risk’, 
‘marginal’, or ‘extended criteria’ deceased donors, in the U.S. each day 30 patients either die or 
are removed from the waiting list because they become too sick to undergo organ transplantation. 
In certain other countries, where there is cultural resistance to deceased donation, e.g., Japan, the 
increased utilization of living donors, e.g., of a single kidney or partial liver, only very partially 
addresses the organ shortage. For transplants of tissues and cells, e.g., pancreatic islet 
transplantation for patients with diabetes, and corneal transplantation for patients with corneal 
blindness (whose numbers worldwide are potentially in the millions), allotransplantation will 
never prove a sufficient source. There is an urgent need for an alternative source of organs and 
cells. The pig could prove to be a satisfactory source, and clinical xenotransplantation using pig 
organs or cells, particularly with the advantages provided by genetic engineering to provide 
resistance to the human immune response, may resolve the organ shortage. The physiologic 
compatibilities and incompatibilities of the pig and the human are briefly reviewed.
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INTRODUCTION
Organ transplantation is an established therapy for a variety of end-stage organ diseases. 
Today, improved surgical techniques and our understanding of the immune system have 
increased survival of patients with organ allografts. In the U.S., more than 617,000 solid 
organ transplants, including kidney, liver, pancreas, intestine, heart, and lung, have been 
performed since 1988 [1]. Worldwide, the numbers are probably at least double the US 
figure. Although most attention has been directed towards transplantation of solid organs, 
corneal transplantation, bone marrow transplantation, isolation and transplantation of cells 
and tissues with specific differentiated functions (e.g., pancreatic islets) represent important 
additional clinical therapies.
The major current problem in organ transplantation is the gap between the number of 
available transplantable organs that become available each year and the number of patients 
waiting for an organ graft (Figure 1) [2]. In the U.S., due to the lack of sufficient 
transplantable organs, each day 30 people either die while waiting for a transplant or are 
removed from the waiting list because they become too sick to undergo a transplant [2].
Significant changes in attitude and law towards organ donation would make increased 
numbers of organs available, but the supply would remain inadequate. In 1991, there were 
6,953 deceased human donors, enabling 15,756 organ transplants to be carried out, and 
23,198 patients on the waiting list. A decade later, in 2001, although there were 12,702 
donors (an 83% increase), enabling 24,239 transplants to be performed (a 54% increase), the 
waiting list had expanded to 79,524 patients (a 243% increase). The significant increase in 
donation was partially the result of the National Organ Transplant Act signed by President 
Ronald Regan in October 1984 [3]. This law was signed 30 years ago and was aimed to 
establish the legal framework for the procurement, donation, and transplantation of organs. 
It was hoped that the law would end the organ shortage. However, the 85% increase in 
donation rate was offset by a 243% increase in patients on the waiting list, which resulted 
from the documented better outcomes after organ transplantation compared to alternative 
therapies.
In the 21st century, the increase in the number of deceased donors and organ transplants has 
not been as significant as before. In 2004, there were 14,154 donors (11% increase from 
2001), 27,040 transplants (11% increase from 2001), and 87,146 patients on the waiting list 
(10% increase from 2001). In the last decade (2004–2013), the increases in the numbers of 
donors and transplants have been minimal or small (a 0.7% increase in donors, and a 7% 
increase in transplants). The increased number of transplants despite virtually no increase in 
the number of donors is associated with (i) the liberalization of acceptance criteria of ‘high-
risk’, ‘marginal’, or ‘extended criteria’ donors, and (ii) the utilization of more organs from a 
single donor. However, during this period, there was a 39% increase in the number of 
patients on the waiting list, which rose to approximately 122,000 [1,2].
The improved medical care that results in the substantial increase in patients on the waiting 
list is a great economic burden to the US (and to other Western countries). For example, 
Medicare covers the costs of care for end-stage renal disease regardless of patient age. In 
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2011, over 500,000 people took advantage of this benefit at a cost of over US$34 billion, 
which is more than 6% of Medicare’s entire budget [4]. If we add the cost of care for other 
end-stage organ failures, $US400 billion is spent each year, which is equivalent to almost 
60% of Medicare’s budget.
According to the World Health Organization, >114,000 organ transplants are carried out 
annually in the world [5,6], which is <10% of global needs. The most frequently 
transplanted organ is the kidney, which accounts for 68% of the total organ transplants. 
Deceased donors account for 60–65% of all transplanted kidneys in many countries. 
However, this rate drops to 5–17% in regions where deceased donation is uncommon for 
religious or cultural reasons, such as the Middle East, Indonesia, and Japan. Although the 
best donation rate in deceased organs (both donation after brain and cardiac deaths) is 
achieved in Spain (36 per million population), organ shortage remains a major big problem 
in Europe [6]. Unfortunately, organ donation does not significantly increase in countries 
with a highly-educated population. In several developed countries, organ donation per 
million remains disappointingly low. For example, in Japan the organ donation rate is only 4 
per million. In most Western countries, it is less than optimal, e.g., in Switzerland it is 12 per 
million, in Canada 15, in the UK 18, and in the US 24 [7].
The donation rate is critical where the needs are greatest, such as in India (1 donor per 
million population) and in China (0.5 donor per million population). In China, about 
300,000 patients would benefit from organ transplants annually, but only about 10,000 
transplants are currently carried out [8], which makes the ratio of supply to demand for 
organ transplants 1:304. However, statistics from the World Health Organization show that 
the mean ratio of organ supply to demand worldwide is 1:25 [9].
In addition, in the US, approximately 30 million patients suffer from diabetes (Types 1 and 
2), and millions more from other disorders that might be potentially amenable to treatment 
by cell or tissue transplantation, e.g., neurodegenerative diseases. Worldwide, the impact is 
even greater since an estimated 340 million people are afflicted by diabetes alone [10].
Although corneal allotransplantation is readily available in the U.S. and in certain other 
countries of the developed world, the worldwide need for human donor corneas far exceeds 
supply, especially in China, India, Korea, and Japan, where cultural and religious concerns 
make it difficult to obtain corneas from human cadavers [11]. For example, in China, there 
are an estimated 4 million people in need of corneal transplantation.
The increased utilization of living organ donors has helped, particularly in countries where 
there is cultural resistance to deceased organ donation, e.g., Japan, but this has had relatively 
little impact on the overall need for organs; some organs, of course, e.g., the heart, clearly 
can only be obtained from deceased donors. Moreover, the shortage of deceased donors and 
the relative success of organ transplants from living donors resulted in the problem of organ 
trafficking, which remains a problem in some parts of the world. It is estimated that 5–10% 
of kidney transplants worldwide result from commercial transactions between a potential 
recipient and a paid living donor [12]. The organ shortage has also lead to the use of organs 
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from executed prisoners in some countries [13]; whether truly informed consent has been 
obtained remains controversial.
It is clear that the current law, rate of organ donation (both deceased and living), and 
liberalized acceptance criteria (i.e., use of high-risk donors, marginal, or extended criteria 
donors) are not enough, and will never be enough to overcome the problem of organ 
shortage.
POTENTIAL OF XENOTRANSPLANTATION
Xenotransplantation, i.e., cross-species transplantation, using pig organs, could resolve the 
shortage of suitable donor organs [14,15]. If pig organs or cells could be transplanted 
successfully into human patients, the advantages would be numerous (Table 1).
Ethically, pigs represent an acceptable choice as an alternative source of organs for humans 
[14,16]. An estimated 100 million pigs are slaughtered in the US each year as sources of 
meat, and 600 million are killed in China to provide heparin. Immunologically, however, the 
pig is less desirable than the nonhuman primate as a source of organs and cells because of 
the genetic distance between pigs and humans. The clinical application of 
xenotransplantation has been held back because it has proved difficult to prevent immune 
injury of pig grafts, a subject that is discussed by several authors elsewhere in this issue. 
Most major advances that have been made in this field have resulted from the introduction 
of genetically-engineered pigs or novel immunosuppressive agents. The current reported 
survival periods of various pig organ and cell transplants in nonhuman primates are 
indicated in Figure 2.
Even if the remaining immunological and biological barriers can be resolved, which seems 
increasingly likely, the question needs to be asked as to whether pig organs will function 
adequately when transplanted to a human host. Ibrahim et al [17] have discussed selected 
physiological compatibilities and incompatibilities between humans and pigs, and these will 
be briefly reviewed here.
Heart
Anatomically, the pig heart is similar, although not identical, to the human heart. 
Physiologically, cardiac output and stroke volume, which are major indicators of cardiac 
function, have been reported to be comparable in pig and human [17]. Mean arterial 
pressure, heart rate, and myocardial blood flow are also nearly identical in the two species. 
The upright posture in humans, in contrast to pigs, does have an evolutionary impact on the 
structure of heart valves but this issue has been proved to be an insignificant problem in pig-
to-nonhuman primate studies [18,19]. The different action potential of cardiomyocytes 
related to morphological differences in the atrioventricuar node between species might 
potentially result in increased arrhythmogenicity of a pig heart transplanted into a human, 
but observations of pig hearts functioning in nonhuman primates for prolonged periods have 
not indicated that this will be a problem [17,18].
Ekser et al. Page 4
Int J Surg. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kidney
The kidney has a major role in maintaining homeostasis, excretion of metabolites, 
electrolyte balance, regulating body fluid and osmolarity. Pig kidney anatomy is remarkably 
similar to the human kidney. The maximum concentrating ability (1080 mOsm/L) and 
glomerular filtration rate (126–175 ml/h) of porcine kidneys are similar to those of human 
kidneys [17]. Kidney function in healthy humans and α1,3-galactosyltransferase gene-
knockout (GTKO) pigs is compared in Table 2. Although serum potassium is slightly higher 
in pigs, the other serum electrolytes, creatinine, and urea nitrogen are similar between pig 
and human. Proteinuria has been identified as an important complication after pig kidney 
xenotransplantation [20–22], but recent evidence suggests it is associated with continuing 
immune activation of the kidney [Iwase H, et al, personal communication]. Pig kidneys have 
been demonstrated to adequately maintain homeostasis, electrolyte balance, and osmolarity 
in nonhuman primates [20,23].
Liver
Pig liver anatomy is slightly different from human liver anatomy. The pig liver has 3 lobes - 
the right lateral, the median, and the left lateral lobes. The median lobe is further subdivided 
by a deep umbilical fissure, which extends almost to the hilum [24]. The inferior vena cava 
is intraparenchymal and runs within the caudate lobe.
The liver has diverse functions, ranging from the synthesis of many vital proteins, 
coagulation factors, and biochemical molecules to detoxification of harmful substances. 
Table 3 compares liver function in healthy humans and pigs. Although there are several 
similarities in hepatic function, alkaline phosphatese (ALP), lactate dehydrogenase (LDH), 
and gamma glutamyltransferase (GGT) are higher in pigs [25,26]. It is more important, 
however, to demonstrate that similarities should not be limited to the measurement of 
enzyme levels, but should compare function as well. Studies by Ekser et al [27], and Kim et 
al [28] suggest that a pig liver may function adequately in a nonhuman primate, producing 
coagulation factors that maintain a normal coagulation profile.
Lung
Although experimental experience with the xenotransplantation of pig lungs is limited, in 
part relating to the severe vasoconstriction that occurs in the newly-transplanted lungs, the 
pig lung has been demonstrated to provide adequate oxygenation and carbon dioxide 
exchange in nonhuman primates [29]. The upright posture of humans may also have an 
impact of physiological function of the pig lung after xenotransplantation. However, due to 
the limited survival achieved with pig lungs in nonhuman primates (<5 days), no definite 
conclusions can be made.
Pancreatic Islets
Porcine insulin differs from human insulin by only one amino acid, and is functionally 
comparable to human insulin. Porcine insulin was used for decades to treat patients with 
diabetes. There is good evidence, therefore, that well-functioning pig islets will be able to 
maintain normoglycemia in diabetic patients [30].
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Neuronal cells
Although there is only one significant study, the evidence is that porcine dopamine-
producing cells can reverse the clinical features of a Parkinson-like disease in monkeys [31].
Corneas
There are similarities between pig and human corneas (Table 4).
CONCLUSIONS
Organ shortage is an undeniable problem in organ transplantation and is increasingly 
problematic. Even if we are able to increase donation rates significantly, allotransplantation 
will never be able to provide sufficient islets for all diabetic patients. As discussed elsewhere 
in this issue, approaches such as stem cell therapy or bioengineered devices are not 
sufficiently successful yet to consider as an alternative to allotransplantation. 
Xenotransplantation is much closer to meaningful clinical trials, and these could be initiated 
either through cellular xenotransplantation [15,30,31] or as a ‘bridge’ to liver [32] or heart 
[33] allotransplantation.
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HIGHLIGHTS
• In the US each day, 30 dead or sick patients are removed from the waiting list
• The available donors are not enough to overcome the global organ shortage
• Pigs represent an alternative source of organs for humans
• The pig could be a satisfactory source of organs for clinical transplantation
• New technologies are facilitating the genetic engineering of pigs
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Figure 1. Trends in the numbers of organ donors (blue), organ transplants (red), and patients on 
the waiting list (black) in the U.S., 1991–2013
In 1991, there were 6,953 donors, 15,757 organ transplants, and 23,198 patients on the 
waiting list. By 2013, there were 14,257 donors, 28,954 organ transplants, and 121,272 
patients on the waiting list. (Data obtained from http://optn.transplant.hrsa.gov.)
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Figure 2. Longest reported survival times of pig organ and cell xenotransplantation in 
preclinical trials (pig-to-nonhuman primate models)
Microencapsulated pancreatic islets = 804 days (with re-Tx), 250 days (without re-Tx) (Sun 
et al [35]) (wild-type [WT] pigs); Neuronal cells = >521 days (Badin et al [31]) (CTLA4-Ig 
transgenic pigs); pancreatic islets = 396 days (van der Windt et al [36]) (hCD46 pigs); 
cornea (full thickness) = >933 days (Choi et al [37]) (WT pigs); hepatocytes = 243 days 
(with re-Tx), 80 days (without re-Tx) (Nagata et al [38]) (WT pigs); heterotopic heart = 
>500 days (Mohiuddin et al [18]) (GTKO/hCD46/hTBM pigs); kidney = >240 days (Tector 
AJ, personal communication) (GTKO/hCD55 pigs); orthotopic heart = 57 days (McGregor 
et al [19]) (GTKO/hCD55 pigs); liver = 9 days (Kim K et al [28]) (hCD55 pigs); lung = 5 
days (Cantu et al [29]) (vWF-deficient pigs). Figure modified from Ekser B et al. [15].
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Table 1
Major advantages of pig organ, tissue, or cell xenotransplantation*
Pigs would be ethically acceptable sources of organs and cells to many of the world’s population
Pigs are easy to breed and have large litters
Pig organs have similarities to human organs in respect of anatomy and physiology
Pigs could provide an unlimited supply of organs, tissues, and cells
The unlimited supply will allow transplantation procedures in ‘borderline’ candidates who might otherwise be declined
Organs will be available immediately and electively
The detrimental effects of brain death on donor organs will be avoided
When bred and housed under ‘clean’ conditions, pigs could provide exogenous infection-free organs, tissues, and cells
The ‘cultural’ barriers to deceased human donation present in some countries, e.g. Japan, will be obviated
Illegal organ trafficking and the use of organs from executed prisoners will be obviated
Organ donation by living donors, with its potential life-threatening complications, will be avoided
*
Modified from Cooper et al [34] and Ekser et al [15].
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Table 2
Comparison of kidney function between healthy humans and GTKO pigs*
Human GTKO** Pig
Sodium (mmol/L) 136–146 144
Potassium (mmol/L) 3.5–5.0 5.3
Chloride (mmol/L) 95–110 103.0
Calcium (mg/dL) 8.4–10.2 10.8
Phosphorus (mg/dL) 2.5–4.5 8.8
CO2 (mmol/L) 21–32 28.1
Urea (mg/dL) 5.0–20.0 12.8
Creatinine (mg/dL) 0.6–1.1 1.1
*Adapted from Ekser et al. [26].
**GTKO = α1,3-galactosyltransferase gene-knockout.
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Table 3
Comparison of liver function in healthy humans and GTKO pigs*
Human GTKO Pig
AST (IU/L) <40 37.0
ALT (IU/L) <40 42.0
ALP (IU/L) 38–126 272
LDH (IU/L) <170 472
GGT (IU/L) <40 74
Tot Bilirubin (mg/dL) 0.3–1.5 0.2
Dir Bilirubin (mg/dL) 0.1–0.4 0.1
Tot Protein (g/dL) 6.3–7.7 5.9
Albumin (g/dL) 3.4–5.0 3.4
Cholesterol (mg/dL) <200 81
Triglyceride (mg/dL) <150 31
Glucose (mg/dL) 70–99 89
PTT (sec) 22.7–35.6 34.1
PT (sec) 11.3–14.5 13.6
INR 0.8–1.2 1.1
D-dimer (micg/mL) <0.45 0.20
Fibrinogen (mg/dL) 200–400 250
Coagulation Factors (U/mL)
 Factor II 0.7–1.3 1.12
 Factor V 0.7–1.5 6.02
 Factor VII 0.6–1.6 2.36
 Factor VIII 0.6–1.5 6.06
 Factor IX 0.6–1.5 4.18
 Factor X 0.7–1.5 1.97
 Factor XI 0.6–1.4 4.07
 Factor XII 0.5–1.7 4.95
 Plasminogen (%) 75–150 3
 Protein C (%) 70–140 11
 Protein S (%) 58–128 11
 Anti-thrombin III (%) 80–120 71
AST= aspartate transaminase, ALT= alanine transaminase, ALP= alkaline phosphatase, LDH= lactate dehydrogenase, GGT= gamma 
glutamyltransferase, INR= international normalized ratio, PT= prothrombin time, PTT= partial thromboplastin time, WT= wild-type, GTKO= 
α1,3-galactosyltransferase gene knock-out.
*Adapted from Ekser et al. [26] and Ekser et al. [25].
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Table 4
Comparison of parameters of corneas between humans and pigs*
Human Pig
Diameter (mm)
 horizontally 11.7 14.9
 vertically 10.6 12.4
Thickness (μm)
 center 536 666
 periphery 593 714
Reactive power (diopter) 43.0 40.4
Tensile strength (MPa) 3.81 3.70
Stress-strain pattern(a) α 42.8 39.3
β 2.97 2.97
Stress-relaxation pattern(b) P(x100) 85.6 64.6
K(−) 0.0165 0.0553
1000s 32% 59%
(a)α is a scale factor. β represents the exponent of the nonlinear relationship between stress and strain
(b)
P is the value of G (t) at the end of the stress-relaxation test. K is the slope of fitted G (t)-In t line.
*Adapted from Hara and Cooper [11].
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